DKK3 (Dickkopf WNT Signaling Pathway Inhibitor 3)

The opposing dysregulation of these markers, reflecting immune checkpoint activation (CD276) and tumor suppressor loss (DKK3), provides a robust and synergistic noninvasive signature. To assess the prognostic value of these two markers, studies involving a larger number of patients and a longer follow-up period are needed.

Notably, DKK3 deficiency in keratinocytes markedly reduces radiation-induced dermal hyperplasia and fibrosis, identifying DKK3 as a key regulator of cutaneous radiation responses. These findings position DKK3 as a promising upstream modulator of TGF-β signaling for mitigating radiation-induced dermatitis and fibrosis, with potential relevance to other fibrotic diseases.

PCL upregulated oncogenic proteins and activated oncogenic signaling pathways. DEPs detectable in the liver and serum indicate potential FALD biomarkers. These findings offer insights into the pathophysiology of FALD and hepatocarcinogenesis and support the development of novel diagnostic and therapeutic strategies.

Collectively, these data demonstrated that MPC1 deficiency promotes melanoma progression via Wnt/β-catenin signaling that is associated with DKK3 regulation. Targeting MPC1-Wnt/β-catenin axis may represent a novel therapeutic strategy for advanced melanoma treatment.

These findings establish PRR11 as an oncogenic driver in RB and highlight the OTUB1-PRR11-DKK3 axis as a regulatory mechanism of Wnt/β-catenin signaling in RB tumorigenesis. Targeting PRR11 and its downstream pathways provides a potential and novel therapeutic strategy for RB treatment.

FA intervention may serve as an effective strategy to restore DKK3 expression to inhibit the Wnt/β-catenin pathway, thereby exerting antitumor activity. Future cervical cancer prevention and treatment strategies may benefit from dynamic monitoring of DKK3 expression to identify potential beneficiaries and provide targeted FA intervention.

Sarcomatoid component-specific DNA hypomethylation of TSKU, PLAU, PLEKHG4, RPSAP52, XBP1 and TRIM2 was correlated with both recurrence-free and overall survival. These data suggest that the DNA methylation alterations associated with sarcomatoid change may participate in malignant progression and determine patient outcome.

Collectively, our findings highlight circRNF10 as a tumor suppressor in driver gene-negative LUAD and suggest that restoring circRNF10 expression represents a promising therapeutic approach for this refractory subtype.

By integrating the latest advancements in basic and clinical research, this article presents a solid theoretical framework for early diagnosis, risk assessment, biomarker development, and precision therapies. It also highlights promising therapeutic targets, including PPARα agonists, mTOR inhibitors, FGF21 analogs, and microbiota interventions, while proposing future directions in multi-omics and personalized treatment strategies.

Low DKK3 protein was an independent risk factor for event-free survival (P = 0.024). DKK3 shows promise as a biomarker for early risk stratification and prognosis prediction in pediatric ALL, potentially supporting personalized treatment strategies.

The multidisciplinary approach, including the tumor board and an infectious disease specialist, are important steps in the effective management of these cases. The role of new biological markers such as CD 276 and DKK 3 for assessing the progression of malignant disease could constitute a new direction for research.

Concordantly, DKK3 expression correlates with IL6-JAK-STAT3 gene signatures in human PDAC datasets. Together, these findings underscore the intricate and context-sensitive role of DKK3, delaying oncogenesis during early stages while paradoxically promoting tumor progression in later stages, suggesting that therapeutic targeting strategies should be approached with caution.